Mazdutide in Singapore: What China’s New Weight Loss Injection Means for Patients Here

Mazdutide is a new injectable weight loss drug approved in China but not currently approved or available in Singapore. Interest in mazdutide has grown significantly across Asia following its approval in China and rising global attention on injectable therapies for obesity and metabolic health.

This article by Sire, a men’s health clinic in Singapore, provides a clear, medically grounded overview of mazdutide, its scientific basis, recent developments in China, and how these trends relate to patients in Singapore. 

Important: Mazdutide is not approved for use in Singapore at the time of writing. This article is for educational purposes only and does not promote or offer any prescription medicine.

What is Mazdutide?

Mazdutide is an injectable investigational medicine developed for the management of obesity and metabolic conditions. In scientific literature, it is also known as IBI362. The drug was developed by Innovent Biologics, a Chinese biopharmaceutical company, with intellectual property rights originally licensed from Eli Lilly for use in Greater China.

What distinguishes mazdutide from earlier therapies is its dual-hormone receptor agonist mechanism. It activates:

• The GLP-1 (glucagon-like peptide-1) receptor, and
• The glucagon receptor

This dual receptor agonist action places mazdutide among a new generation of metabolic drugs designed to address both appetite regulation and energy expenditure, rather than appetite suppression alone.

How Does Mazdutide Work in the Body?

Understanding how mazdutide works requires understanding the hormones it targets.

GLP-1: Appetite, Satiety, and Blood Sugar Control

GLP-1 is a hormone released after eating. It plays a role in:

• Increasing insulin secretion when blood sugar rises
• Slowing digestion, which promotes fullness
• Reducing appetite

Many established diabetes and weight-related treatment work primarily through this pathway.

Glucagon: Energy Use and Fat Metabolism

Glucagon has a different but complementary role:

• It signals the liver to release stored energy
• It promotes fat metabolism
• It increases overall energy expenditure

Mazdutide’s dual agonist receptor design aims to balance reduced caloric intake with increased metabolic activity, a weight reduction strategy that has attracted interest among researchers studying obesity as a chronic metabolic disease.

What Do Clinical Studies Show About Mazdutide?

Clinical trials are conducted in carefully selected populations under controlled conditions. Findings from clinical research help regulators and clinicians evaluate safety and effectiveness but do not guarantee the same outcomes for every individual.

Findings from Early and Mid-Stage Clinical Research

Phase 1 and Phase 2 studies of mazdutide in Chinese adults with overweight or obesity reported:

• Statistically significant reductions in body weight compared with placebo
• Decreases in waist circumference and BMI
• Improvements in metabolic markers related to insulin sensitivity

These findings supported the progression to larger Phase 3 trials in Chinese adults.

Phase 3 Trials and Published Results

Several Phase 3 trials have since evaluated mazdutide over longer periods. Results published in major medical journals like the New England Journal suggest that:

• Weight reduction was sustained over time in Chinese participants
• Effects were dose-dependent
• Side effect profiles were broadly similar to other GLP-1 based therapies

Experts have noted that the drug’s performance in trials appears comparable to established therapies, with potential additional metabolic effects due to its dual mechanism. However, long-term safety data and post-marketing surveillance for adverse events are still limited outside China.

China’s Approval: Why It Matters Globally

In mid-2025, China approved mazdutide as its first domestically developed weight loss injection, marking a milestone in the country’s biopharmaceutical development.

Addressing Rising Obesity in China

China has seen a rapid rise in overweight and obesity over the past three decades. More than half of its population is now classified as overweight, and national projections suggest this figure may rise further by 2030.

Mazdutide’s approval aligns with China’s broader public health strategy, which frames obesity as a serious medical condition rather than a cosmetic issue. The approval also reflects growing confidence in domestic innovation, reducing reliance on imported medicines.

Challenging Western Dominance in Obesity Drugs

Until recently, the global weight loss drug market has been dominated by Western pharmaceutical companies. Drugs containing semaglutide (e.g. Wegovy) or tirzepatide (e.g. Mounjaro) have attracted widespread attention, but their high cost has limited access in many regions.

Mazdutide’s approval signals the beginning of increased competition. As patents for older GLP-1 drugs approach expiry in China, domestic firms are developing both biosimilars and new injectable therapies, potentially reshaping pricing and access within Asia. 

This has led some commentators to describe mazdutide as part of a wave of new weight loss drugs from China, although regulatory approval outside China remains limited.

Is Mazdutide a “Generic Weight Loss Injection from China”?

This is a common misconception we receive from our patients, but it is important to clarify.

Mazdutide is not a generic drug. Generics are copies of medicines whose patents have expired. Mazdutide is a new, patented molecule with a distinct mechanism of action.

However, China is expected to produce generic or biosimilar versions of older GLP-1 drugs as patents expire. 

How Does Mazdutide Compare With Other Injectable Weight Loss Treatments?

Mazdutide is often compared with other injectable metabolic therapies because they share some overlapping mechanisms.

Mechanism Differences

• Single-pathway injections primarily target GLP-1
• Dual-pathway injections, such as mazdutide, target both GLP-1 and glucagon receptors

This difference may influence metabolic outcomes, but direct comparisons require careful interpretation of clinical trial data.

Cost and Access Considerations

In China, mazdutide initially entered the market at a price point between older GLP-1 drugs and newer dual agonist therapies. Over time, prices may change due to procurement policies and market competition. 

In Singapore, however, cost discussions are theoretical, as the drug is not approved for use.

Is Mazdutide Available in Singapore?

No. Mazdutide is not approved by Singapore’s Health Sciences Authority (HSA) and is not available for prescription or sale in Singapore.

Singapore has strict regulatory standards for medicines, particularly injectable therapies. Approval requires comprehensive review of:

• Clinical trial data
• Safety profiles
• Manufacturing quality
• Plans for post-approval monitoring of adverse events

Even if a drug is approved in another country, it cannot be prescribed locally until HSA approval is granted.

Should Patients in Singapore Buy Weight Loss Injections from Overseas?

Some people searching for “mazdutide Singapore” may also encounter online listings for China weight loss injections or similar products in clinical development.

Healthcare professionals strongly advise against this. Risks include:

• Counterfeit or substandard products
• Improper storage and handling
• Incorrect dosing
• Lack of medical supervision

Injectable medications should only be used under the care of a licensed doctor and within the local regulatory framework.

What Side Effects Have Been Reported in Clinical Studies?

In clinical trials, side effects reported with mazdutide among Chinese patients have been similar to those seen with other GLP-1 based therapies. These include:

• Nausea
• Vomiting
• Diarrhoea
• Reduce appetite
• Injection-site reactions

Most side effects among Chinese patients were reported during early treatment phases and were generally mild to moderate. However, broader safety data in diverse populations is still limited.

Approved Approaches to Weight Management in Singapore

While new drugs from China and elsewhere attract attention, safe and approved approaches to weight management already exist in Singapore.

At clinics such as Sire, weight management typically focuses on:

• Comprehensive health assessment
• Identification of hormonal or metabolic contributors
• Nutrition and lifestyle support
• Clinically approved treatments when appropriate

Weight management is best approached as a long-term medical strategy, not a short-term solution.

Key Takeaways for Patients

• Mazdutide represents a significant scientific development, particularly in China
• It is part of a broader shift in how obesity is treated medically
• It is not available or approved in Singapore
• Regulatory approval, not media coverage, determines clinical use
• Safe, approved weight management care is already accessible locally

Final Thoughts

The growing interest in Mazdutide Singapore reflects wider changes in global metabolic healthcare. China’s approval of its first home-grown weight loss drug highlights how rapidly this field is evolving, but it also underscores the importance of regulation, evidence, and patient safety.

At Sire, our role is to help patients navigate these developments with clarity and realism – separating scientific progress from speculation, and focusing on care that is appropriate, approved, and medically responsible in Singapore.

If you are concerned about body weight, metabolic health, or hormonal balance, speaking with a qualified healthcare professional remains the most reliable first step.